---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-017704"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:22:42.032622+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback

## Summary
- Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).
- FY2025 revenue guidance raised to >$500M; FY2026 to >$625M; adjusted EBITDA guidance >$235M and >$340M, respectively.
- Board authorized $500M share repurchase program (~8% of market cap); timing and amount discretionary.
- Debt reorganized: $30M borrowed on revolver to repay term loan; revolver outstanding $72.5M, term loan $2.5M; cost of debt down 1.1%.
- FDA-approved yield enhancement process expected to increase IG output 20% from same plasma volume, supporting future growth.

## SEC filing metadata
- accession: 0001140361-25-017704
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/0001140361-25-017704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/ef20048524_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-017704
- JSON: https://secwatch.observer/filing/0001140361-25-017704.json
- Plain text: https://secwatch.observer/filing/0001140361-25-017704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.